Trials / Active Not Recruiting
Active Not RecruitingNCT03614949
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic body radiation therapy (SBRT) | SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites. |
| DRUG | Atezolizumab | Atezolizumab 1200 mg intravenously (IV) every 3 weeks. |
Timeline
- Start date
- 2019-01-29
- Primary completion
- 2028-10-01
- Completion
- 2028-10-01
- First posted
- 2018-08-03
- Last updated
- 2026-04-01
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03614949. Inclusion in this directory is not an endorsement.